This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Alnylam Stock Down Despite Positive Phase III Givosiran Data
by Zacks Equity Research
Alnylam (ALNY) reports positive phase III data on investigational candidate, givosiran. Despite the results, its shares slipped almost 4% on investors' concern regarding adverse events.
Ligand Sells Promacta Rights for $827M, Updates '19 View
by Zacks Equity Research
Ligand Pharmaceuticals (LGND) announces sale of all rights to Novartis' Promacta, including royalty payments on global sales, to Royalty Pharma.
Aduro (ADRO) Q4 Earnings and Revenues Fall Shy of Estimates
by Zacks Equity Research
Wider-than-expected loss affects Aduro (ADRO) in the fourth quarter. Also, revenues lag estimates.
Ophthotech's (OPHT) Q4 Loss Wider, Gene Therapy in Focus
by Zacks Equity Research
Ophthotech (OPHT) reports wider-than-expected loss in the fourth quarter. It boosts gene therapy pipeline through new agreements and acquisitions.
Biotech ETFs Jump on Roche-Spark Deal
by Sweta Killa
The news of Roche-Spark Deal has triggered speculations of merger wave in the gene therapy industry and pushed the biotech ETFs higher.
Alkermes' (ALKS) and Biogen's NDA for BIIB098 Accepted by FDA
by Zacks Equity Research
The FDA accepts Alkermes (ALKS) and partner Biogen's NDA for diroximel fumarate and sets an action date in the fourth quarter of 2019.
Novartis In-Licenses Rights to Heart Candidate From Ionis
by Zacks Equity Research
Novartis (NVS) in-licenses rights to develop and commercialize TQJ230 from Ionis Pharmaceuticals for treating targeted cardiovascular diseases.
Roche (RHHBY) to Acquire Spark Therapeutics for $4.8 Billion
by Zacks Equity Research
Roche (RHHBY) to acquire Philadelphia-based gene therapy company, Spark Therapeutics, Inc. (ONCE) at a price of $114.50 per share in an all-cash transaction.
AbbVie's RA Candidate Upadacitinib Gets FDA Priority Review
by Zacks Equity Research
AbbVie's (ABBV) new drug application for its late-stage candidate, upadacitinib, gets a priority review status from the FDA for treating rheumatoid arthritis in adult patients.
Roche's (RHHBY) BLA for Lymphoma Drug Gets Priority Review
by Zacks Equity Research
The FDA accepts Roche's (RHHBY) BLA for polatuzumab vedotin and NDAs for entrectinib, and grants Priority Review status to the applications.
Incyte (INCY) Q4 Earnings Miss Estimates, Revenues Beat
by Zacks Equity Research
Incyte's (INCY) fourth-quarter earnings miss estimates but revenues beat the same on strong Jakafi sales.
The Zacks Analyst Blog Highlights: ExxonMobil, Merck, Danaher, Novartis and Expedia
by Zacks Equity Research
The Zacks Analyst Blog Highlights: ExxonMobil, Merck, Danaher, Novartis and Expedia
Conatus (CNAT) Completes Enrollment in Phase II NASH Study
by Zacks Equity Research
Conatus (CNAT) completes enrollment in a phase IIb study on emricasan, being developed for the treatment of patients with fibrosis or cirrhosis caused by NASH.
Key Takeaways from Eli Lilly's (LLY) Q4 Earnings Report
by Zacks Equity Research
Here are the key takeaways from Eli Lilly's (LLY) fourth-quarter earnings conference call.
Top Research Reports for ExxonMobil, Merck & Danaher
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including ExxonMobil (XOM), Merck (MRK) and Danaher (DHR).
Aduro Initiates Dosing in Phase I Melanoma Study on ADU-S100
by Zacks Equity Research
Aduro (ADRO) doses the first patient in a phase I study on ADU-S100 in combination with Yervoy for the treatment of relapsed and refractory melanoma. Shares rise.
Is a Disappointment in Store for Incyte (INCY) Q4 Earnings?
by Zacks Equity Research
Investors are looking forward to Jakafi's performance and other pipeline updates when Incyte (INCY) reports Q4 results on Feb 14.
Tilray (TLRY) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Investors will focus on pipeline progress and updates when Tilray (TLRY) reports fourth-quarter results.
Incyte Down as FDA Extends Review Period of Jakafi for GVHD
by Zacks Equity Research
The FDA extends the review period of Incyte's (INCY) sNDA for the label expansion of Jakafi for the treatment of acute GVHD.
Ligand (LGND) Beats on Q4 Earnings & Sales, Raises '19 View
by Zacks Equity Research
Ligand (LGND) beats earnings and sales estimates for the fourth quarter of 2018 and raises 2019 guidance.
Vanda (VNDA) Q4 Earnings: What's in Store for the Stock
by Zacks Equity Research
On Vanda's (VNDA) fourth-quarter 2018 conference call, investor focus will be on the sales figure of its two marketed drugs, Hetlioz and Fanapt.
Glaxo (GSK) Beats on Q4 Earnings, to Focus on Oncology in '19
by Zacks Equity Research
Glaxo (GSK) beats earnings and sales estimates in the fourth quarter. Strong sales growth of vaccine portfolio boosts sales. However, Advair generic will severely impact the drug's U.S. sales.
Glaxo Inks Deal With Merck KGaA to Co-Develop Cancer Candidate
by Zacks Equity Research
Glaxo (GSK) signs a co-development and commercialization agreement with Germany-based Merck KGaA for the latter's next-generation immunotherapy candidate, M7824.
Roche Submits sBLA to FDA for Label Expansion of Kadcyla
by Zacks Equity Research
Roche (RHHBY) submits sBLA for Kadcyla to the FDA for adjuvant treatment of patients with HER2-positive early breast cancer with residual disease after neoadjuvant treatment.
Gilead (GILD) Q4 Earnings Miss Estimates, Revenues Beat
by Zacks Equity Research
A mixed fourth-quarter for biotech bigwig Gilead as it misses on earnings but beat on revenues.